Incidence and outcome of SARS-CoV-2 infection in a pediatric kidney transplant recipient cohort from a single center in Northern ItalyArticle Published on 2022-11-012022-11-16 Journal: Pediatric transplantation [Category] COVID19(2023년), SARS, 치료기술, [키워드] adolescents children clinically Cohort concern contrary COVID-19 criteria detect duration of symptom Effect eight enrolled epidemiological high risk hospital Immunocompromised patients incidence IQR Italy kidney kidney transplant mortality rate Nasopharyngeal swab observation period outcome Patient pediatric pediatric kidney transplant pediatric transplantation performed Population positive patients positive RT-PCR recipient recipients renal required risk RT-PCR RT-PCR test RT-PCR testing SARS-CoV-2 SARS-COV-2 infection severe COVID-19 single center solid organ transplant solid organ transplant. solid organ transplantation SOT specific treatment Swab symptomatic Test tested the healthy therapy [DOI] 10.1111/petr.14335 PMC 바로가기
Outcomes following SARS-CoV-2 infection in individuals with and without solid organ transplantation-A Danish nationwide cohort studyArticle Published on 2022-11-012022-11-16 Journal: American journal of transplantation : official jou [Category] COVID19(2023년), SARS, 변종, [키워드] 95%CI acute respiratory syndrome analysis assisted respiration calculate clinical research/practice Cohort cohort study comparable Contact coronavirus Cox regression death Effect General population hospital Hospitalization incidence rate increased risk increased the risk individual Infection infection and infectious agents - viral infection and infectious agents - viral: SARS-CoV-2/COVID-19 infectious agent Infectious disease lower risk Mortality omicron organ performed recipient reduce reduced risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine SARS-CoV2 infection severe COVID-19 solid organ transplant solid organ transplantation solid organ transplantation. vaccination Vaccinations variant were used with COVID-19 [DOI] 10.1111/ajt.17142 PMC 바로가기
Association between SARS-CoV-2 infection and de novo HLA donor specific antibody production in lung transplant recipients: Single-center studyArticle Published on 2022-11-012022-11-15 Journal: Human immunology [Category] SARS, 진단, 치료기술, [키워드] antibody antibody production association COVID-19 COVID-19 pandemic de novo diagnosed with COVID-19 Diagnosis Donor donor specific antibodies HLA HLA antibodies HLA class I incidence include Infection LTR lung transplant lung transplant. MFI morbidity and mortality no significant difference outcome performed raised recipient recipients respiratory retrospective SARS-COV-2 infection the median viral infection [DOI] 10.1016/j.humimm.2022.07.007 PMC 바로가기
Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant RecipientsArticle Published on 2022-11-012022-11-15 Journal: Clinical gastroenterology and hepatology : the off [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] acute respiratory syndrome anti-S anti-SARS-CoV-2 antibody Antibody Response Antibody titer cellular Cellular immune response coronavirus COVID-19 defined domain dose filtration first vaccination HCs healthy control humoral immune response Immunosuppression increase increase in investigated liver liver transplant liver transplant recipients LTR LTRs Lymphocyte count mRNA mRNA-based non-responders Odds ratio Patient Prospective Study RBD recipient responders response risk factor SARS-CoV-2 SARS-CoV-2 vaccination second vaccination Seroconversion seronegative seropositive spike-specific T-cell response T cells the median Third and Fourth SARS-CoV-2 Vaccination. Transplant vaccination Vaccinations [DOI] 10.1016/j.cgh.2022.06.028 PMC 바로가기
Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccinesArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] SARS, 변종, 진단, [키워드] 95% CI 95% confidence interval Ad26.COV2-S Administered Admission adverse event adverse events adverse events. age analyzed anti-SARS-CoV-2 vaccine BNT162b2 calculated Campylobacter jejuni ChAdOx1 collected CoronaVac COVID-19 diarrhea died dose doses epidemiological Guillain-barrè syndrome immunization inactivated incidence interquartile range Intravenous immunoglobulin male median Mild mRNA-1273 mRNA-based Patient performed plasma positive provided recipient reported risk SARS-CoV-2 Seven Surveillance survivor symptom onset syndrome tested treated vaccination Vaccine Vaccines variant [DOI] 10.1111/ene.15504 PMC 바로가기
Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients – targeting the target antigenArticle Published on 2022-11-012022-11-15 Journal: Bone marrow transplantation [Category] SARS, 진단, [키워드] Antigen Booster vaccine CAR-T dose recipient SARS-CoV-2 [DOI] 10.1038/s41409-022-01795-3 PMC 바로가기
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyArticle Published on 2022-11-012022-11-15 Journal: The Lancet. Gastroenterology & Hepatology [Category] SARS, 진단, [키워드] adjusted age All participant anti-SARS-CoV-2 anti-TNF antibody Antibody binding antibody concentration Antibody concentrations approved available data boost booster case-control study combination therapy Concentration control group COVID-19 COVID-19 vaccine Diagnosis disease dose Evidence first dose geometric mean geometric mean ratio group groups had no healthy control healthy individuals heterologous vaccine homologous IBD Immunosuppressed immunosuppressed patient immunosuppressive Immunosuppressive treatment Infection Inflammatory bowel disease jak inhibitors multicentre multivariable nine no significant difference Older Older age participant Patient patients treated Pfizer Primary outcome receiving Receptor binding domain recipient recruited reduced regimen response S1 RBD SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination significantly significantly lower Support T-cell Response T-cell responses the healthy therapy Tofacitinib Treatment ulcerative colitis Vaccine vaccine dose vaccine doses vaccine-induced antibody response VIP were measured [DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine RecipientsArticle Published on 2022-10-292022-11-15 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ACE2 acute respiratory syndrome antibodies antibodies. antibody binding coronavirus coronavirus 2 COVID-19 individual inhibited levels of antibody messenger Messenger RNA no difference omicron recipient recipients respiratory response responses against RNA SARS-CoV-2 significantly lower Spike protein T cells T-cell Response T-cell responses Vaccine vaccine strain variant while [DOI] 10.1093/cid/ciac305 PMC 바로가기
Notes From the Field: Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability – United States, December 23, 2021-August 28, 2022Article Published on 2022-10-282022-11-15 Journal: Morbidity and Mortality Weekly Report [Category] 치료제, [키워드] Analysis Antiviral collected COVID-19 COVID-19 therapeutics Critical death Department Dispensing distribution drug Emergency use authorization EUA FDA food higher risk highlight Hospitalization Human indicated Intervention medication medium Mild Moderate COVID-19 molnupiravir oral Patient Paxlovid provide recipient reduce risk service United States vulnerability [DOI] 10.15585/mmwr.mm7143a3 PMC 바로가기
Neutralization of SARS-CoV-2 Omicron and Delta Variants in Relation to Vaccine-Induced Antibody Levels in Kidney Transplant Recipients and Healthy ControlsArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Abstract Control COVID-19 Delta kidney transplant kidney transplant recipients Level Neutralizing Neutralizing antibodies omicron PRNT recipient relation SARS-CoV-2 Transplant Vaccines Vaccines. [DOI] 10.1128/spectrum.01314-22 PMC 바로가기